| 
 | 
 | 
 | 
| LEADER | 
01000caa a22002652c 4500 | 
| 001 | 
NLM31060396X | 
| 003 | 
DE-627 | 
| 005 | 
20250227085543.0 | 
| 007 | 
cr uuu---uuuuu | 
| 008 | 
231225s2020    xx |||||o     00| ||eng c | 
| 024 | 
7 | 
  | 
|a 10.1016/j.clim.2020.108483 
  |2 doi 
   | 
| 028 | 
5 | 
2 | 
|a pubmed25n1035.xml 
   | 
| 035 | 
  | 
  | 
|a (DE-627)NLM31060396X 
   | 
| 035 | 
  | 
  | 
|a (NLM)32479989 
   | 
| 035 | 
  | 
  | 
|a (PII)S1521-6616(20)30080-2 
   | 
| 040 | 
  | 
  | 
|a DE-627 
  |b ger 
  |c DE-627 
  |e rakwb 
   | 
| 041 | 
  | 
  | 
|a eng 
   | 
| 100 | 
1 | 
  | 
|a Zhao, Lu 
  |e verfasserin 
  |4 aut 
   | 
| 245 | 
1 | 
0 | 
|a Immunostaining of galactose-deficient IgA1 by KM55 is not specific for immunoglobulin A nephropathy 
   | 
| 264 | 
  | 
1 | 
|c 2020 
   | 
| 336 | 
  | 
  | 
|a Text 
  |b txt 
  |2 rdacontent 
   | 
| 337 | 
  | 
  | 
|a ƒaComputermedien 
  |b c 
  |2 rdamedia 
   | 
| 338 | 
  | 
  | 
|a ƒa Online-Ressource 
  |b cr 
  |2 rdacarrier 
   | 
| 500 | 
  | 
  | 
|a Date Completed 01.02.2021 
   | 
| 500 | 
  | 
  | 
|a Date Revised 01.02.2021 
   | 
| 500 | 
  | 
  | 
|a published: Print-Electronic 
   | 
| 500 | 
  | 
  | 
|a Citation Status MEDLINE 
   | 
| 520 | 
  | 
  | 
|a Copyright © 2020 Elsevier Inc. All rights reserved. 
   | 
| 520 | 
  | 
  | 
|a BACKGROUND: Immunoglobulin A nephropathy (IgAN nephropathy, IgAN) is named for the renal pathological features of IgA-dominant immunoglobulin deposition. IgA deposits, however, may also occur in other diseases, from liver disease and inflammation to chronic infections and tumors. Now increasing studies have suggested that galactose-deficient IgA1 (Gd-IgA1) plays a critical role in the pathogenesis of IgAN. This study aims to investigate whether the Gd-IgA1-specific antibody KM55 contributes to differentiating primary IgAN from other diseases with IgA deposits 
   | 
| 520 | 
  | 
  | 
|a METHODS: In this retrospective study, we enrolled 100 Chinese patients with IgA deposits in renal biopsies, including IgAN(n = 40), IgAN with hepatitis B virus antigen deposits(n = 14), IgA vasculitis(n = 16), lupus nephritis(n = 11), incidental IgA deposits(n = 13) and negative controls(n = 6). Double immunostaining of Gd-IgA1 and IgA was performed in all biopsies 
   | 
| 520 | 
  | 
  | 
|a RESULTS: There were similar patterns of Gd-IgA1 deposition in primary IgAN, IgA vasculitis, and IgAN with hepatitis B virus antigen deposits. Gd-IgA1 staining could also be seen in patients with lupus nephritis and incidental IgA deposits, but the intensity was significantly lower than IgAN, and the optimal cutoff was 2+ staining for differential diagnosis. Every increase in KM55 staining intensity of 1+ was associated with an increase in the odds of primary IgAN (OR: 4.399; 95% CI: 1.725-11.216) 
   | 
| 520 | 
  | 
  | 
|a CONCLUSIONS: Immunostaining for Gd-IgA1 by KM55 is not specific for IgA nephropathy, but weak or negative staining may favor incidental IgA deposits 
   | 
| 650 | 
  | 
4 | 
|a Journal Article 
   | 
| 650 | 
  | 
4 | 
|a Research Support, Non-U.S. Gov't 
   | 
| 650 | 
  | 
4 | 
|a Galactose-deficient IgA1 
   | 
| 650 | 
  | 
4 | 
|a Hepatitis B virus 
   | 
| 650 | 
  | 
4 | 
|a IgA 
   | 
| 650 | 
  | 
4 | 
|a IgA nephropathy 
   | 
| 650 | 
  | 
4 | 
|a IgA vasculitis 
   | 
| 650 | 
  | 
4 | 
|a Renal biopsy 
   | 
| 650 | 
  | 
7 | 
|a Immunoglobulin A 
  |2 NLM 
   | 
| 650 | 
  | 
7 | 
|a Galactose 
  |2 NLM 
   | 
| 650 | 
  | 
7 | 
|a X2RN3Q8DNE 
  |2 NLM 
   | 
| 700 | 
1 | 
  | 
|a Peng, Liang 
  |e verfasserin 
  |4 aut 
   | 
| 700 | 
1 | 
  | 
|a Yang, Danyi 
  |e verfasserin 
  |4 aut 
   | 
| 700 | 
1 | 
  | 
|a Chen, Shi 
  |e verfasserin 
  |4 aut 
   | 
| 700 | 
1 | 
  | 
|a Lan, Zhixin 
  |e verfasserin 
  |4 aut 
   | 
| 700 | 
1 | 
  | 
|a Zhu, Xuejing 
  |e verfasserin 
  |4 aut 
   | 
| 700 | 
1 | 
  | 
|a Yuan, Shuguang 
  |e verfasserin 
  |4 aut 
   | 
| 700 | 
1 | 
  | 
|a Chen, Guochun 
  |e verfasserin 
  |4 aut 
   | 
| 700 | 
1 | 
  | 
|a Liu, Yu 
  |e verfasserin 
  |4 aut 
   | 
| 700 | 
1 | 
  | 
|a Liu, Hong 
  |e verfasserin 
  |4 aut 
   | 
| 773 | 
0 | 
8 | 
|i Enthalten in 
  |t Clinical immunology (Orlando, Fla.) 
  |d 1999 
  |g 217(2020) vom: 30. Aug., Seite 108483 
  |w (DE-627)NLM098196855 
  |x 1521-7035 
  |7 nnas 
   | 
| 773 | 
1 | 
8 | 
|g volume:217 
  |g year:2020 
  |g day:30 
  |g month:08 
  |g pages:108483 
   | 
| 856 | 
4 | 
0 | 
|u http://dx.doi.org/10.1016/j.clim.2020.108483 
  |3 Volltext 
   | 
| 912 | 
  | 
  | 
|a GBV_USEFLAG_A 
   | 
| 912 | 
  | 
  | 
|a SYSFLAG_A 
   | 
| 912 | 
  | 
  | 
|a GBV_NLM 
   | 
| 912 | 
  | 
  | 
|a GBV_ILN_11 
   | 
| 912 | 
  | 
  | 
|a GBV_ILN_24 
   | 
| 912 | 
  | 
  | 
|a GBV_ILN_350 
   | 
| 951 | 
  | 
  | 
|a AR 
   | 
| 952 | 
  | 
  | 
|d 217 
  |j 2020 
  |b 30 
  |c 08 
  |h 108483 
   |